Pregabalin Capsule
Product Images NDC 71205-696

Product Visual Gallery

This gallery contains 13 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 71205-696). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Proficient Rx Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Pregabalin 01)

Chemical structure of Pregabalin, showing its molecular framework including an amino group, carboxyl group, and an isobutyl side chain, consistent with the generic drug Pregabalin structure.*

FDA Label Image

Figure 1 (Pregabalin 02)

A line graph showing the percent of patients improved against percent improvement in pain from baseline. It compares four groups: Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, Pregabalin 25 mg three times a day, and placebo. The graph illustrates higher improvement percentages with increased Pregabalin dosages compared to placebo.*

FDA Label Image

Figure 2 (Pregabalin 03)

A line graph comparing the percent of patients improved versus percent improvement in pain from baseline. It depicts two groups: one receiving Pregabalin 100 mg three times a day and a placebo group. The x-axis represents percent improvement in pain from baseline, and the y-axis represents the percent of patients improved, showing higher improvement rates for the Pregabalin group compared to placebo.*

FDA Label Image

Figure 3 (Pregabalin 04)

A line graph comparing the percent of patients improved against percent improvement in pain from baseline among groups receiving Pregabalin 300 mg, 150 mg, 75 mg twice daily, and placebo. The graph shows higher improvement percentages with increasing Pregabalin doses compared to placebo.*

FDA Label Image

Figure 4 (Pregabalin 05)

A line graph showing the percent of patients improved versus percent improvement in pain from baseline. It compares three groups: Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, and placebo, with separate lines for each. The y-axis represents the percent of patients improved, and the x-axis shows percent improvement in pain from baseline, from 0 to 100 percent.*

FDA Label Image

Figure 5 (Pregabalin 06)

A line graph showing the percent of patients improved on the vertical axis against percent improvement in pain from baseline on the horizontal axis. It compares three groups: Pregabalin 100 mg three times a day, Pregabalin 50 mg three times a day, and Placebo, with each group represented by dashed, solid, and dotted lines respectively.*

FDA Label Image

Figure 6 (Pregabalin 07)

Bar chart titled 'Study E1' and 'Study E3' depicting responder rate percentages across various doses of Pregabalin and placebo. The horizontal axis lists treatments including placebo and Pregabalin doses ranging from 50 mg/day to 600 mg/day, with administration frequencies BID or TID. The vertical axis shows responder rate percentages from 0% to 60%. Study E1 displays increasing responder rates from placebo (14%) to 600 mg/day BID (51%). Study E3 shows responder rates ranging from placebo (9%) to 600 mg/day TID (49%). Sample sizes for each group are indicated below the bars.*

FDA Label Image

Figure 7 (Pregabalin 08)

A line graph showing median percent change from baseline in seizure reduction versus dose in mg/day. The graph includes data points from four different studies labeled E1 BID, E2 TID, E3 BID, and E3 TID, with significant p-values noted at various doses, illustrating seizure reduction increasing with dose.*

FDA Label Image

Figure 9 (Pregabalin 09)

A line chart depicting percent of patients improved versus percent improvement in pain from baseline, comparing Pregabalin dosed at 600 mg, 450 mg, and 300 mg daily to placebo. Four curves illustrate patient response rates across different levels of pain improvement.*

FDA Label Image

Figure 10 (Pregabalin 10)

A Kaplan-Meier survival curve comparing Pregabalin and Placebo over 180 days. The y-axis shows the estimated percentage of subjects without LTR (loss to response), while the x-axis represents days. The Pregabalin group shows a higher percentage of subjects without LTR compared to Placebo throughout the study period.*

FDA Label Image

Figure 11 (Pregabalin 11)

A line chart comparing the percent of subjects improved over time from baseline to Week 12 using BOCF. The X-axis represents the percent improved from baseline to week 12 BOCF, ranging from >0 to 100. The Y-axis represents the percent of subjects improved, ranging from 0 to 100. Two lines are shown: a solid line for Pregabalin and a dashed line for Placebo, with Pregabalin consistently showing a higher percentage of subjects improved.*

FDA Label Image

Figure 12 (Pregabalin 12)

A line chart comparing the percent of subjects improved from baseline to Week 16 with Pregabalin versus placebo. The x-axis represents the percent improved, ranging from 0 to over 100, and the y-axis shows the percent of subjects improved, from 0 to 100 percent. Two lines depict results for Pregabalin and placebo groups, showing the trend of improvement over the study period.*

FDA Label Image

71205-696-60 (Pregabalin 14)

Pregabalin 50 mg capsules label showing product of Proficient Rx LP. The label indicates 60 capsules per container with each capsule containing 50 mg pregabalin. Capsules are described as size 3 hard gelatin with white opaque cap and body, marked with "SG" and "351" in black ink. Manufacturer is ScieGen Pharmaceuticals, Inc., Hauppauge, NY.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.